Comparison between intravitreal bevacizumab and posterior sub-tenon injection of triamcinolone acetonide in macular edema secondary to retinal vein occlusion

Figures & data

Table 1 Baseline characteristics of patients with macular edema secondary to retinal vein occlusion

Treatment groups	IVIA (n=23)	PSTA (n=22)	p-value
Age (years), mean (SD)	63 (13)	70 (13)	0.07*
Sex, % (n)
Male	56.5% (13)	68.2% (15)	0.42**
Female	43.5% (10)	31.8% (7)
Diagnosis, % (n)
BRVO	69.6% (16)	77.3% (17)	0.56**
CRVO	30.4% (7)	22.7% (5)
Nonperfused PCN, %	40% (6/15)	50% (6/12)	0.60**
Lens status, % (n)
Phakia	17.4% (4)	22.7% (5)	0.72**
Pseudophakia	82.6% (19)	77.3% (17)
Baseline BCVA, mean (SD)	0.78 (0.46)	0.91 (0.46)	0.21*
Baseline IOP, mean (SD)	14.4 (3.1)	12.8 (2.9)	0.08*
Baseline CMT, mean (SD)	478 (126)	419 (125)	0.09*

Note:

* Mann–Whitney U-test,

** χ² test or Fisher’s exact test.

Abbreviations: BCVA, best-corrected visual acuity; BRVO, branch retinal vein occlusion; CMT, central macular thickness (µm); CRVO, central retinal vein occlusion; IOP, intraocular pressure (mmHg); IVIA, intravitreal injection of bevacizumab; PCN, perifoveal capillary network; PSTA, posterior sub-tenon injection of triamcinolone acetonide.

Table 2 Comparisons of primary outcome measures following treatment between groups

Outcome measures	IVIA	p-value	PSTA	p-value	p-value for between groups
logMAR BCV A, mean (SD)
Baseline	0.78 (0.46)		0.91 (0.46)		0.21
Month 1	0.60 (0.39)	0.006	0.81 (0.49)	0.16	0.09
Month 3	0.57 (0.33)	0.001	0.79 (0.50)	0.038	0.12
Month 6	0.56 (0.36)	0.001	0.87 (0.47)	0.13	0.02
CMT (µm), mean (SD)
Baseline	478 (126)		419 (125)		0.09
Month 1	272 (94)	<0.001	347 (103)	0.002	0.006
Month 3	273 (79)	<0.001	332 (117)	0.001	0.03
Month 6	295 (113)	<0.001	350 (115)	0.012	0.065

Abbreviations: BCVA, best-corrected visual acuity; CMT, central macular thickness (µm); IVIA, intravitreal injection of bevacizumab; PSTA, posterior sub-tenon injection of triamcinolone acetonide.

Table 3 IOP after intravitreal Avastin or sub-tenon Kenacort treatment

IOP, mean (SD)	IVIA	p-value	PSTA	p-value	p-value for between groups
Baseline	14.4 (3.1)		12.8 (2.9)		0.08
Month 1	15.3 (3.0)	0.059	14.4 (5.5)	0.12	0.21
Month 3	14.7 (3.6)	0.66	16.0 (4.4)	0.002	0.41
Month 6	14.0 (3.4)	0.38	13.3 (3.3)	0.41	0.55

Abbreviations: IOP, intraocular pressure (mmHg); IVIA, intravitreal injection of bevacizumab; PSTA, posterior sub-tenon injection of triamcinolone acetonide.

Figure 1 Graph representing the comparison of IOP change (mmHg, mean ± SEM), mean between the 2 groups at 1, 3 and 6 months following treatment.

Abbreviations: IOP, intraocular pressure; SEM, standard error of the mean.

Figure 2 Kaplan–Meier survival analysis of first recurrence of macular edema.

Note: The 2 curves represent the cumulative proportion of recurrence-free intervals for the IVIA and PSTA groups.
Abbreviations: IVIA, intravitreal injection of bevacizumab; PSTA, posterior sub-tenon injection of triamcinolone acetonide.

Table 4 Prognostic factors for BCVA at 6 months by linear regression analysis

Clinical factors	Coefficient	p-value*	Coefficient	p-value**
Age	0.017	0.001	0.007	0.043
Sex	−0.041	0.75	−0.009	0.911
Baseline BCVA	0.754	<0.001	0.78	<0.001
Diagnosis	−0.372	0.012	−0.091	0.38
Treatment	−0.219	0.16	−0.118	0.22
Lens status	−0.107	0.48	−0.018	0.85

Notes:

* p-value after adjustment for age and sex.

** p-value after adjustment for age, sex and baseline BCVA.

Abbreviation: BCVA, best-corrected visual acuity.